Lilly registers 2,001-person Phase 3 trial of orforglipron in people with overweight

Eli Lilly has registered a Phase 3 trial of orforglipron, its oral GLP-1 pill, in 2,001 people who have overweight and are at risk of developing obesity-related complications or of progressing to class 1 obesity ^[1]. The study is listed as not yet recruiting ^[1]. Its stated population points the drug toward preventing weight-related disease, rather than treating people who already have obesity ^[1].

Orforglipron is the molecule sold as Foundayo, which Lilly recently won approval for ^[2]. Regulatory reviews for the pill are ongoing in more than 40 markets, and Lilly plans a regulatory submission for Foundayo's use in type 2 diabetes this year ^[2]. The new Phase 3 registration does not list a start date or an expected completion date ^[1]. Whether the trial's main measure is weight change, progression to obesity, or something else has not been reported ^[1].

The registration describes participants as being at risk of progressing to class 1 obesity, which means they are not yet in that category ^[1]. That is a narrower starting point than a trial in people who already have obesity. The entry also does not say how long participants will be followed or whether Lilly intends to seek a prevention-type indication for the drug. None of that has been disclosed ^[1].

The context is a market that is already large and still growing. Obesity therapeutics reached $66 billion in sales last year and could rise to between $105 billion and $200 billion by 2027 and beyond, according to IQVIA ^[2]. A temporary Medicare GLP-1 Bridge program that began in July could grow coverage by an estimated 35% and give access to around 20 million potential patients, the investment bank William Blair wrote in a report cited by BioSpace ^[2]. Whether Medicare or commercial insurers would cover a prevention-style use of orforglipron has not been disclosed.

Why it matters for patients

Most GLP-1 obesity labels are built around treating people who already have obesity or who have overweight plus a related health condition. A trial that enrolls people earlier in that path, with the goal of keeping them from progressing, could eventually make the drugs available to a larger group than the current labels cover ^[1].

That outcome is not guaranteed and would depend on results and on regulators. Two things are unknown: whether the trial will succeed, and whether Lilly will seek a label for this group. Neither has been disclosed ^[1].

Cost and coverage sit at the center of that question. The Medicare program that expanded access to obesity medicines in July is described as temporary ^[2]. Adding a much larger, less sick population to the pool of people who might qualify would put more pressure on that program and on commercial plans. How payers would handle a prevention indication has not been reported.

Orforglipron is a once-daily pill, not an injection, which is one reason more patients are being prescribed the drug: roughly 1.5 million people were taking Novo Nordisk's rival oral Wegovy pill as of July, according to William Blair ^[2].

What happens next

• The 2,001-person Phase 3 is listed as not yet recruiting, with no start date reported ^[1].
• Lilly plans a regulatory submission for Foundayo in type 2 diabetes this year ^[2].
• Lilly also plans a submission for the next-generation obesity drug retatrutide in obesity and overweight in the early months of 2027 ^[2].
• The Medicare GLP-1 Bridge program is described as temporary, and its longer-term status has not been reported ^[2].